Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1274

Human IgG4-S228P kappa, isotype control

Home » Antibodies » Human IgG4-S228P kappa, isotype control

Background of Human IgG4-S228P kappa, isotype control

Isotype controls are a type of primary antibodies that lack specificity to the target, but match the class and type of the primary antibody used in in vitro and in vivo studies. Isotype controls are often used to measure the level of non-specific background signal caused by binding non-specifically to Fc receptors on the cell surface, or other cellular molecules. Chinese hamster ovary (CHO) host cell line is the most popular mammalian system of therapeutic proteins production. The isotype controls produced by CHO line share similar posttranslational modifications with the therapeutic proteins, especially in N‐linked glycosylation, which are useful benchmark in the discovery and development of therapeutic antibodies.

Specifications

Catalog Number:
KB-1274
Antibody Name:
Human IgG4-S228P kappa, isotype control
Isotype:
Human IgG4-S228P, kappa
FC Muations:
Target:
HEL
Species Reactivity:
Chicken
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to Effector Functions. Front. Immunol. 5, (2014).
  2. Zhong, X. et al. Transient CHO expression platform for robust antibody production and its enhanced N-glycan sialylation on therapeutic glycoproteins. Biotechnol. Prog. 35, e2724 (2019).